Efficacy and safety of thermomechanical fractional injury-assisted corticosteroid delivery versus intralesional corticosteroid injection for the treatment of hypertrophic scars: A randomized split-scar trial
Issued Date
2022-04-01
Resource Type
ISSN
01968092
eISSN
10969101
Scopus ID
2-s2.0-85121369472
Pubmed ID
34913497
Journal Title
Lasers in Surgery and Medicine
Volume
54
Issue
4
Start Page
483
End Page
489
Rights Holder(s)
SCOPUS
Bibliographic Citation
Lasers in Surgery and Medicine Vol.54 No.4 (2022) , 483-489
Suggested Citation
Manuskiatti W. Efficacy and safety of thermomechanical fractional injury-assisted corticosteroid delivery versus intralesional corticosteroid injection for the treatment of hypertrophic scars: A randomized split-scar trial. Lasers in Surgery and Medicine Vol.54 No.4 (2022) , 483-489. 489. doi:10.1002/lsm.23511 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/86012
Title
Efficacy and safety of thermomechanical fractional injury-assisted corticosteroid delivery versus intralesional corticosteroid injection for the treatment of hypertrophic scars: A randomized split-scar trial
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Background: Disruption of the natural skin barrier in a controlled manner may be used to deliver drugs that enhance scar resolution. Objective: To compare the efficacy and safety of thermomechanical fractional injury (TMFI)-assisted topical corticosteroid delivery with corticosteroid injection in the treatment of hypertrophic scar (HTS). Materials and Methods: This was a randomized, split-scar, double-blinded study. Twenty-one subjects with HTS on the abdomen received five split-scar treatments of TMFI + Steroid and steroid injection alone. Changes in scar thickness, scar volume, and Vancouver Scar Scale (VSS) were analyzed. Patient self-assessment, VAS scores, and adverse effects were also evaluated. Results: Scar thickness, volume, and VSS scores of both segments improved significantly compared to baseline. On every follow-up visit, there were no significant differences in mean scar thickness reduction between the two treatment groups except at the 6-month follow-up where the mean scar thickness reduction of the steroid injection segment was significantly lower than that of the TMFI + Steroid segment (95% confidence interval [CI], 0.09–0.35; p = 0.002). Scar volume, VSS scores, and patient self-assessment also showed no significant differences between both segments on all visits. The steroid injection segment was significantly more painful than the TMFI + Steroid segment (95% CI, −2.16 to −1.29; p < 0.001). Adverse effects of skin atrophy, telangiectasia, and post-inflammatory hyperpigmentation were noted in the steroid injection segment, while no adverse effects were observed at the TMFI + Steroid segment. Conclusions: TMFI-assisted topical corticosteroid delivery is an effective treatment for HTS with a lower risk of adverse effects compared with corticosteroid injection.